Clinical Trial Update: A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, pharmacokinetics, and 18F radiation dosimetry of the PET radiotracer CTT1057 in prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CTT1057 (CTT1057)

Snippet

Sponsor: Cancer Targeted Technology | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED